139 related articles for article (PubMed ID: 2433342)
1. Probing functional sites on complement protein B with monoclonal antibodies. Evidence for C3b-binding sites on Ba.
Ueda A; Kearney JF; Roux KH; Volanakis JE
J Immunol; 1987 Feb; 138(4):1143-9. PubMed ID: 2433342
[TBL] [Abstract][Full Text] [Related]
2. Residual hemolytic and proteolytic activity expressed by Bb after decay-dissociation of C3b,Bb.
Fishelson Z; Müller-Eberhard HJ
J Immunol; 1984 Mar; 132(3):1425-9. PubMed ID: 6229580
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the interaction between properdin and factor B, components of the alternative-pathway C3 convertase of complement.
Farries TC; Lachmann PJ; Harrison RA
Biochem J; 1988 Aug; 253(3):667-75. PubMed ID: 3140783
[TBL] [Abstract][Full Text] [Related]
4. Alternative complement pathway activation fragment Ba binds to C3b. Evidence that formation of the factor B-C3b complex involves two discrete points of contact.
Pryzdial EL; Isenman DE
J Biol Chem; 1987 Feb; 262(4):1519-25. PubMed ID: 3643213
[TBL] [Abstract][Full Text] [Related]
5. C3 convertase of the human alternative pathway of complement: modulation of enzyme activity and stability by mouse monoclonal antibodies to Bb.
Fishelson Z; Müller-Eberhard HJ
Eur J Immunol; 1987 Feb; 17(2):303-4. PubMed ID: 3644748
[TBL] [Abstract][Full Text] [Related]
6. Heparin prevents formation of the human C3 amplification convertase by inhibiting the binding site for B on C3b.
Maillet F; Kazatchkine MD; Glotz D; Fischer E; Rowe M
Mol Immunol; 1983 Dec; 20(12):1401-4. PubMed ID: 6558419
[TBL] [Abstract][Full Text] [Related]
7. Stabilization of the amplification convertase of complement by monoclonal antibodies directed against human factor B.
Daha MR; Deelder AM; Van Es LA
J Immunol; 1984 May; 132(5):2538-42. PubMed ID: 6232321
[TBL] [Abstract][Full Text] [Related]
8. Segment spanning residues 727-768 of the complement C3 sequence contains a neoantigenic site and accommodates the binding of CR1, factor H, and factor B.
Becherer JD; Alsenz J; Esparza I; Hack CE; Lambris JD
Biochemistry; 1992 Feb; 31(6):1787-94. PubMed ID: 1371073
[TBL] [Abstract][Full Text] [Related]
9. C3 convertase of human complement: enhanced formation and stability of the enzyme generated with nickel instead of magnesium.
Fishelson Z; Müller-Eberhard HJ
J Immunol; 1982 Dec; 129(6):2603-7. PubMed ID: 6923908
[TBL] [Abstract][Full Text] [Related]
10. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor.
Fischer E; Kazatchkine MD; Mecarelli-Halbwachs L
Eur J Immunol; 1984 Dec; 14(12):1111-4. PubMed ID: 6240408
[TBL] [Abstract][Full Text] [Related]
11. Differences between the binding sites of the complement regulatory proteins DAF, CR1, and factor H on C3 convertases.
Pangburn MK
J Immunol; 1986 Mar; 136(6):2216-21. PubMed ID: 2419425
[TBL] [Abstract][Full Text] [Related]
12. Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells.
Pangburn MK; Müller-Eberhard HJ
Proc Natl Acad Sci U S A; 1978 May; 75(5):2416-20. PubMed ID: 276881
[TBL] [Abstract][Full Text] [Related]
13. A circulating inhibitor of fluid-phase amplification. C3 convertase formation in systemic lupus erythematosus.
Waldo FB; Forristal J; Beischel L; West CD
J Clin Invest; 1985 Jun; 75(6):1786-95. PubMed ID: 3159752
[TBL] [Abstract][Full Text] [Related]
14. The C3/C5 convertase of the alternative pathway of complement: stabilization and restriction of control by lanthanide ions.
Fishelson Z; Müller-Eberhard HJ
Mol Immunol; 1983 Mar; 20(3):309-15. PubMed ID: 6553181
[TBL] [Abstract][Full Text] [Related]
15. C5 convertase of the alternative complement pathway: covalent linkage between two C3b molecules within the trimolecular complex enzyme.
Kinoshita T; Takata Y; Kozono H; Takeda J; Hong KS; Inoue K
J Immunol; 1988 Dec; 141(11):3895-901. PubMed ID: 3183384
[TBL] [Abstract][Full Text] [Related]
16. Isolation and characterization of a 33,000-dalton fragment of complement Factor B with catalytic and C3b binding activity.
Lambris JD; Müller-Eberhard HJ
J Biol Chem; 1984 Oct; 259(20):12685-90. PubMed ID: 6567645
[TBL] [Abstract][Full Text] [Related]
17. The C3 convertase of the alternative pathway of human complement. Enzymic properties of the bimolecular proteinase.
Pangburn MK; Müller-Eberhard HJ
Biochem J; 1986 May; 235(3):723-30. PubMed ID: 3638964
[TBL] [Abstract][Full Text] [Related]
18. Ba and Bb fragments of factor B activation: fragment production, biological activities, neoepitope expression and quantitation in clinical samples.
Kolb WP; Morrow PR; Tamerius JD
Complement Inflamm; 1989; 6(3):175-204. PubMed ID: 2472921
[TBL] [Abstract][Full Text] [Related]
19. The activation of the C3b feedback cycle with human complement components. II. Using components of the alternative pathway.
Mak LW; Majewski J; Lachmann PJ
Clin Exp Immunol; 1977 Nov; 30(2):211-21. PubMed ID: 606443
[TBL] [Abstract][Full Text] [Related]
20. Regulation by membrane sialic acid of beta1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway.
Fearon DT
Proc Natl Acad Sci U S A; 1978 Apr; 75(4):1971-5. PubMed ID: 273923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
